Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Thumbnail
URI
http://hdl.handle.net/11287/620392
Author
James, N D
de Bono, J S
Spears, M R
Clarke, NW
Mason, M D
Dearnaley, D P
Ritchie, A W S
Amos, C L
Gilson, C
Jones, R J
Matheson, D
Millman, R
Attard, G
Chowdhury, S
Cross, W R
Gillessen, S
Parker, C C
Russell, J M
Berthold, D R
Brawley, C
Adab, F
Aung, San
Birtle, A J
Bowen, J
Brock, S
Chakraborti, P
Ferguson, C
Gale, J
Gray, E
Hingorani, M
Hoskin, P J
Lester, J F
Malik, Z I
McKinna, F
McPhail, N
Money-Kyrle, J
O'Sullivan, J
Parikh, O
Protheroe, A
Robinson, A
Srihari, N N
Thomas, C
Wagstaff, J
Wylie, J
Zarkar, A
Parmar, M K B
Sydes, M R
Date
2017-07
Journal
The New England journal of medicine
Type
Journal Article
Publisher
New England Journal of Medicine
DOI
10.1056/NEJMoa1702900
Rights
Archived with thanks to The New England journal of medicine
Metadata
Show full item record
Abstract
Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design.
Citation
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 2017, 377 (4):338-351 N. Engl. J. Med.
Publisher URL
http://www.nejm.org/doi/abs/10.1056/NEJMoa1702900?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
Collections